Blueprint Medicines (FRA:2L9) Accounts Payable & Accrued Expense : €65.7 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Accounts Payable & Accrued Expense?

Blueprint Medicines's quarterly accounts payable & accrued expense increased from Sep. 2023 (€62.6 Mil) to Dec. 2023 (€65.8 Mil) but then declined from Dec. 2023 (€65.8 Mil) to Mar. 2024 (€65.7 Mil).

Blueprint Medicines's annual accounts payable & accrued expense increased from Dec. 2021 (€85.9 Mil) to Dec. 2022 (€88.8 Mil) but then declined from Dec. 2022 (€88.8 Mil) to Dec. 2023 (€65.8 Mil).

Blueprint Medicines Accounts Payable & Accrued Expense Historical Data

The historical data trend for Blueprint Medicines's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Accounts Payable & Accrued Expense Chart

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

71.98

67.17

85.91

88.80

65.84

Blueprint Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															84.30	63.14	62.57	65.84	65.72

Blueprint Medicines Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Blueprint Medicines (FRA:2L9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (FRA:2L9) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

BPMC:USA 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (FRA:2L9) Headlines

No Headlines